Eric Dremel Appointed President of Medacta USA, Inc.

Medtech veteran will lead U.S business for world’s sixth-biggest orthopedic manufacturer

CHICAGO--()--Medacta® International, a privately held, family-owned global leader in the design of innovative joint replacement and spine surgery products, today announced that Eric Dremel has been named president of the company’s United States subsidiary, Medacta USA, Inc., headquartered in Chicago, Illinois.

Dremel is a veteran medical technology executive with more than 27 years of experience in the development and commercialization of orthopedic products. He most recently served as general manager of Medacta USA’s Joint Reconstruction Division after joining the company in 2012. Previously, he spent nine years at DePuy Orthopaedics as vice president of sales. While at DePuy, Dremel formulated and implemented sales strategies that tripled U.S. revenues. Dremel went on to join the teams that founded Moximed and Amp Orthopedics, two venture backed companies developing novel technologies for the treatment of osteoarthritis. His background also includes senior marketing and sales management roles with Stryker and Zimmer.

“For over fifteen years, Medacta has been committed to responsible innovation, exceptional products, and comprehensive education and training for surgeons around the world,” said Francesco Siccardi, executive vice president of Medacta International. “Eric’s experience building successful orthopedics businesses makes him the ideal choice to lead Medacta USA and position it for long-term success in this large and growing market.”

Dremel’s appointment comes as Medacta prepares to recognize the opening of its new U.S. headquarters in Chicago in late June. The opening event will coincide with two highly anticipated medical education events in the city: the first Advanced AMIS® (Anterior Minimally Invasive Surgery) course at Northwestern University, as well as the 158th AMIS Learning Center for surgeons new to anterior hip surgery. Pioneered by Medacta and leading orthopedic surgeons, AMIS is a muscle-sparing technique for total hip replacement that has been associated with shortened recovery time, fewer complications, and improved patient outcomes.

“Since entering the market in 2009, Medacta USA has experienced rapid year-over-year growth, and its products have received accolades from surgeons and patients nationwide,” said Dremel. “2014 will be an important year for Medacta USA as we open our new headquarters, expand our distribution network, and debut compelling new products that deliver benefits to patients, surgeons, and the healthcare system at large. In my new role, I look forward to working with the U.S. team to build on our current success and deliver sustained, profitable growth.”

About Medacta® International

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a holistic approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in 26 countries. The company’s U.S. business unit, Medacta USA, Inc., is headquartered in Chicago, Illinois. For more information about the company, please visit www.medacta.com.

Contacts

Media Relations for Medacta
Hal Mackins, +1-617-379-3775
hal@torchcommunications.com

Contacts

Media Relations for Medacta
Hal Mackins, +1-617-379-3775
hal@torchcommunications.com